Overview

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer
Treatments:
Ketamine